184 related articles for article (PubMed ID: 28151053)
1. A systematic review of modifiable risk factors in the progression of multiple sclerosis.
Hempel S; Graham GD; Fu N; Estrada E; Chen AY; Miake-Lye I; Miles JN; Shanman R; Shekelle PG; Beroes JM; Wallin MT
Mult Scler; 2017 Apr; 23(4):525-533. PubMed ID: 28151053
[TBL] [Abstract][Full Text] [Related]
2. A systematic review of the effects of modifiable risk factor interventions on the progression of multiple sclerosis.
Hempel S; Graham GD; Fu N; Estrada E; Chen AY; Miake-Lye I; Miles JN; Shanman R; Shekelle PG; Beroes JM; Wallin MT
Mult Scler; 2017 Apr; 23(4):513-524. PubMed ID: 28151074
[TBL] [Abstract][Full Text] [Related]
3. Smoking and worsening disability in multiple sclerosis: A meta-analysis.
Heydarpour P; Manouchehrinia A; Beiki O; Mousavi SE; Abdolalizadeh A; -Lakeh MM; Sahraian MA
Acta Neurol Scand; 2018 Jul; 138(1):62-69. PubMed ID: 29542102
[TBL] [Abstract][Full Text] [Related]
4. Cigarette Smoking, Alcohol Consumption and Overweight in Multiple Sclerosis: Disability Progression.
Paz-Ballesteros WC; Monterrubio-Flores EA; de Jesús Flores-Rivera J; Corona-Vázquez T; Hernández-Girón C
Arch Med Res; 2017 Jan; 48(1):113-120. PubMed ID: 28577864
[TBL] [Abstract][Full Text] [Related]
5. Smoking and multiple sclerosis: A systematic review and meta-analysis using the Bradford Hill criteria for causation.
Degelman ML; Herman KM
Mult Scler Relat Disord; 2017 Oct; 17():207-216. PubMed ID: 29055459
[TBL] [Abstract][Full Text] [Related]
6. Association of Vitamin D Levels With Multiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1b.
Fitzgerald KC; Munger KL; Köchert K; Arnason BG; Comi G; Cook S; Goodin DS; Filippi M; Hartung HP; Jeffery DR; O'Connor P; Suarez G; Sandbrink R; Kappos L; Pohl C; Ascherio A
JAMA Neurol; 2015 Dec; 72(12):1458-65. PubMed ID: 26458124
[TBL] [Abstract][Full Text] [Related]
7. Vitamin D status and the risk of multiple sclerosis: a systematic review and meta-analysis.
Duan S; Lv Z; Fan X; Wang L; Han F; Wang H; Bi S
Neurosci Lett; 2014 Jun; 570():108-13. PubMed ID: 24769422
[TBL] [Abstract][Full Text] [Related]
8. Factors associated with onset, relapses or progression in multiple sclerosis: A systematic review.
McKay KA; Jahanfar S; Duggan T; Tkachuk S; Tremlett H
Neurotoxicology; 2017 Jul; 61():189-212. PubMed ID: 27045883
[TBL] [Abstract][Full Text] [Related]
9. Vitamin D deficiency is associated with disability and disease progression in multiple sclerosis patients independently of oxidative and nitrosative stress.
Oliveira SR; Simão ANC; Alfieri DF; Flauzino T; Kallaur AP; Mezzaroba L; Lozovoy MAB; Sabino BS; Ferreira KPZ; Pereira WLCJ; Kaimen-Maciel DR; Dichi I; Reiche EMV
J Neurol Sci; 2017 Oct; 381():213-219. PubMed ID: 28991684
[TBL] [Abstract][Full Text] [Related]
10. The efficacy of vitamin D in multiple sclerosis: A meta-analysis.
Zheng C; He L; Liu L; Zhu J; Jin T
Mult Scler Relat Disord; 2018 Jul; 23():56-61. PubMed ID: 29778041
[TBL] [Abstract][Full Text] [Related]
11. Smoking does not influence disability accumulation in primary progressive multiple sclerosis.
Javizian O; Metz LM; Deighton S; Koch MW
Eur J Neurol; 2017 Apr; 24(4):624-630. PubMed ID: 28239937
[TBL] [Abstract][Full Text] [Related]
12. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
[TBL] [Abstract][Full Text] [Related]
13. Tobacco smoking and disability progression in multiple sclerosis: United Kingdom cohort study.
Manouchehrinia A; Tench CR; Maxted J; Bibani RH; Britton J; Constantinescu CS
Brain; 2013 Jul; 136(Pt 7):2298-304. PubMed ID: 23757766
[TBL] [Abstract][Full Text] [Related]
14. The association of serum 25-hydroxyvitamin D levels with multiple sclerosis severity and progression in a case-control study from China.
Zhang Y; Liu G; Han X; Dong H; Geng J
J Neuroimmunol; 2016 Aug; 297():127-31. PubMed ID: 27397085
[TBL] [Abstract][Full Text] [Related]
15. Vitamin D for the management of multiple sclerosis.
Jagannath VA; Fedorowicz Z; Asokan GV; Robak EW; Whamond L
Cochrane Database Syst Rev; 2010 Dec; (12):CD008422. PubMed ID: 21154396
[TBL] [Abstract][Full Text] [Related]
16. Cigarette smoking and progression in multiple sclerosis.
Koch M; van Harten A; Uyttenboogaart M; De Keyser J
Neurology; 2007 Oct; 69(15):1515-20. PubMed ID: 17923613
[TBL] [Abstract][Full Text] [Related]
17. Alcohol, coffee, fish, smoking and disease progression in multiple sclerosis.
D'hooghe MB; Haentjens P; Nagels G; De Keyser J
Eur J Neurol; 2012 Apr; 19(4):616-24. PubMed ID: 22117611
[TBL] [Abstract][Full Text] [Related]
18. Modifiable risk factors of COVID-19 in patients with multiple sclerosis: a single-centre case-control study.
Montini F; Nozzolillo A; Rancoita PMV; Zanetta C; Moiola L; Cugnata F; Esposito F; Rocca MA; Martinelli V; Filippi M
J Neurol; 2023 Apr; 270(4):1835-1842. PubMed ID: 36795147
[TBL] [Abstract][Full Text] [Related]
19. [Smoking and multiple sclerosis].
Arruti M; Castillo-Triviño T; Egüés N; Olascoaga J
Rev Neurol; 2015 Feb; 60(4):169-78. PubMed ID: 25670047
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the Expanded Disability Status Scale and the Multiple Sclerosis Functional Composite as clinical endpoints in multiple sclerosis clinical trials: quantitative meta-analyses.
Bin Sawad A; Seoane-Vazquez E; Rodriguez-Monguio R; Turkistani F
Curr Med Res Opin; 2016 Dec; 32(12):1969-1974. PubMed ID: 27603119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
